title: [Intra-lesional beta-interferon in combination with systemic thymopentin. Evaluation of results in 35 cases of CIN III and 2 cases of VAIN associated with HPV].
abstract: We performed an open study on 37 patients (average age 35 years), with CIN III or VAIN III and Viral Cytopatic Effects (VCE), who underwent a new standardized bifasic therapy by means of intralesional beta-interferon, topic beta-interferon and subcutaneous timopentine injection. Each therapeutic and checking step was made by colposcopic and microcolpohysteroscopic inspection, which showed spreading necrotic zones in the dysplastic places and peripheral typical epithelium replacement. Microcolpohysteroscopy allowed us to obtain correct diagnosis of the lesion and its location, to discriminate each pathologic aspects (CIN, VAIN, VCE), to perform an adeguated biopsy and intralesional therapy and to follow-up lesion course without repeated biopsies. After two months of therapy as maximum safety limit, we performed conization (in CIN case) in order to confirm the effects of therapy by hystology and especially to evaluate the deep lesional border. The istologic examination underlined the previous microcolpohysteroscopic report of dysplastic regression until its disapperance, with lasting VCE in all the cases.
authors.affiliation: Ospedale Ginecologico-Ostetrico, Sant'Anna, Torino.
authors.forename: G
authors.initials: G
authors.lastname: Osnengo
authors.forename: G
authors.initials: G
authors.lastname: Maina
authors.forename: G
authors.initials: G
authors.lastname: Gordini
authors.forename: A
authors.initials: A
authors.lastname: Durando
authors.forename: C
authors.initials: C
authors.lastname: Bertone
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000287:Administration, Topical; D003588:Cytopathogenic Effect, Viral; D015344:DNA Probes, HPV; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000627:therapeutic use; D027383:Papillomaviridae / Q000187:drug effects / Q000276:immunology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D016305:Thymopentin; D013946:Thymopoietins / Q000008:administration & dosage / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*; D014412:Tumor Virus Infections / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D002578:Uterine Cervical Dysplasia / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D014623:Vaginal Diseases / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
chemical_list: D000276:Adjuvants, Immunologic; D015344:DNA Probes, HPV; D007370:Interferon Type I; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D016305:Thymopentin
vernacular_title: beta-interferone intralesionale più timopentina sistemica. Valutazione su 35 CIN III e 2 VAIN III associate ad HPV.